CBPartners is a leading global healthcare strategy consulting firm

Thought Leadership

Part II: Non-Traditional Players Attempting Entry into the Healthcare Sector

In part two of this series about non-traditional players in the healthcare space, CBPartners dives into one company’s (Walmart) recently established partnership with a traditional pharmaceutical company (Novo Nordisk) to investigate the larger ramifications of these new entrants for key stakeholders – patients, the pharmaceutical industry, and their traditional competition.

Part I: Non-Traditional Players Attempting Entry Into the Healthcare Sector

In part one of this two-part series about non-traditional players in the healthcare sector, CBPartners explores the increasingly attractive market despite the risk of an expensive failed venture by analyzing the success and failures of four non-traditional players.

Exploring the Impact of COVID-Driven Trends on the US Healthcare Landscape

CBPartners reviews the COVID-driven changes to patients, providers, payers, clinical research, and pharmaceutical distribution within the US.

Verily to Acquire SignalPath, Expanding the Company’s Clinical Research Capabilities

Verily recently announced its first major acquisition, a software platform known as SignalPath. The acquisition would fold SignalPath into Baseline, Verily’s clinical research platform.

What Market Access Opportunities Exist for Oncology Products in China? An Analysis of Oncology Product Inclusion in the 2020 NRDL

Fourteen oncology drugs were successfully negotiated and included in the 2020 NRDL. As the new prices became effective from March 01, 2021, several key features and trends have been observed.

Latest career opportunities

New York City, San Francisco, London
Summer Analyst (Internship)
Apply
New York City, San Francisco, London
Manager, Commercial Strategic Planning
Apply
New York City, San Francisco, London
Analyst
Apply